Thursday - April 30, 2026

Nucleic Acid Isolation and Purification Market to Reach $10.99 Billion by 2030, Driven by NGS Expansion and Precision Diagnostics

Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA), Application (Diagnostics, Personalized Medicine), End User (CROs), Region – Global Forecast to 2030 The global Nucleic Acid Isolation and Purification … Continue reading

Medical Device Manufacturing Equipment Market to Hit $27.80 Billion by 2030

Medical Device Manufacturing Equipment (by Production) Market by Type (Material Processing, Sterilization & Cleaning Equipment), Application (Consumables & Disposables), End User (OEMs, Contract Manufacturing Organizations) – Global Forecast to 2030 According to MarketsandMarkets™, the global Medical Device Manufacturing Equipment Market … Continue reading

Secure Access Service Edge Market Technological Advancements, Future Growth, Business Scenario and Top Key Companies To 2032

Cisco Systems (US), HPE (US), Verizon (US), Broadcom (US), Fortinet (US), Akamai (US), Oracle (US), Extreme Networks (US), AT&T (US), Palo Alto Networks (US), Checkpoint Software Technologies (Israel), Huawei (China). Secure Access Service Edge (SASE) Market by Offering (SD-WAN, SSE), … Continue reading

eGRC Market Growth Factors, Overview, Size, Share, Drivers, Top Companies, and Future Scope To 2030

MetricStream (US), Archer Technologies (US), IBM (US), ServiceNow (US), SAP SE (Germany), Diligent (US), AuditBoard (US), NAVEX Global (US), LogicManager (US), Riskonnect (US), Wolters Kluwer (Netherlands), SAS Institute (US), SAI360 (US). eGRC Market by Solution (Risk Management, Compliance Management, Policy … Continue reading

ENDRA Life Sciences (NASDAQ: NDRA) Heats Up as Diagnostic Play Targeting GLP-1 Bottleneck – See Comparison Stocks Inside

While investors chase the GLP-1 drug boom, a critical bottleneck is emerging that could reshape the entire market—liver imaging simply doesn’t scale to meet the coming demand. As metabolic dysfunction–associated steatotic liver disease (MASLD) and GLP-1 therapies continue to expand … Continue reading